Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Bacteremia: early-phase trial registry

2 of 12 indexed Bacteremia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 2 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Bacteremia: 12 US clinical trials tracked, 2 recruiting.

Bacteremia is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is T2 Biosystems, running 1 of these trials.

Enrollment posture brief

Registry condition bacteremia

OPEN 2 | RECR 17% | LATE 0 | EARLY 3 | RANK #1429 | SPON 1

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Bacteremia (this)17%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Bacteremia

Bacteremia lists 2 open slots (17% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Bacteremia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Bacteremia is recruiting below its size-band peers.

    2 of 12 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Bacteremia trials is spread across many organizations.

    T2 Biosystems accounts for 1 of 12 trials (8.3%). 12 distinct sponsors appear on at least one study for this condition label.

  3. Typical Bacteremia enrolment sits around 1,354 participants.

    Median target enrolment is 1,354 among the 12 trials that report a genuine target (sentinel values excluded). 2 of those (16.7%) plan for fewer than 100 participants.

  4. Bacteremia splits between interventional and observational designs.

    6 interventional and 6 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21

Open and recent trials

12 total, page 1 of 1

RECRUITING NA 320 participants

Reducing Risk for Infective Endocarditis

Wake Forest University Health Sciences

NCT05721781

RECRUITING 126 participants

Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge

Methodist Health System

NCT07486362

ACTIVE NOT RECRUITING 50,000 participants

Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia

Henry Ford Health System

NCT05296590

COMPLETED NA 14,889 participants

Multicenter Blood Culture Quality Improvement

Vanderbilt University

NCT01413555

COMPLETED 10,000 participants

Comparison of Infection Rates Among Patients Using Two Catheter Access Devices

Emory University

NCT00965198

COMPLETED NA 3,622 participants

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Sunnybrook Health Sciences Centre

NCT03005145

COMPLETED 2,430 participants

T2Bacteria Panel Pivotal Study

T2 Biosystems

NCT02535468

COMPLETED 1,354 participants

Virulence Determinants in S Aureus Bacteremia

Duke University

NCT00319826

COMPLETED 330 participants

Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock

University of British Columbia

NCT01867905

COMPLETED Phase 1 208 participants

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

Cook County Health

NCT00130221

COMPLETED Phase 2 40 participants

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

M.D. Anderson Cancer Center

NCT01321879

COMPLETED Phase 1 27 participants

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

Genentech

NCT03162250

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Named interventions

Most-linked intervention names on Bacteremia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Telavancin Drug
1 trials
DSTA4637S Drug
1 trials
Daily bathing with Bar soap Other
1 trials
2% chlorhexidine gluconate impregnated cloth Drug
1 trials
Blood Culture QI Program Other
1 trials
14 days of adequate antibiotic treatment. Other
1 trials
7 days of adequate antibiotic treatment Other
1 trials
SOC Drug
1 trials

US sites by state

Facility locations filed on Bacteremia trials. A trial with sites in several states counts in each.

Michigan 4 trials
North Carolina 3 trials
Texas 2 trials
New York 2 trials
Tennessee 1 trials
Rhode Island 1 trials
Pennsylvania 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Bacteremia page

12 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bacteremia condition card totals 12 registered trials; most-linked intervention Telavancin; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.